Advertisement

Pflügers Archiv

, Volume 447, Issue 5, pp 735–743 | Cite as

The equilibrative nucleoside transporter family, SLC29

  • Stephen A. Baldwin
  • Paul R. Beal
  • Sylvia Y. M. Yao
  • Anne E. King
  • Carol E. Cass
  • James D. Young
The ABC of Solute Carriers Guest Editor: Matthias A. Hediger

Abstract

The human SLC29 family of proteins contains four members, designated equilibrative nucleoside transporters (ENTs) because of the properties of the first-characterised family member, hENT1. They belong to the widely-distributed eukaryotic ENT family of equilibrative and concentrative nucleoside/nucleobase transporters and are distantly related to a lysosomal membrane protein, CLN3, mutations in which cause neuronal ceroid lipofuscinosis. A predicted topology of 11 transmembrane helices with a cytoplasmic N-terminus and an extracellular C-terminus has been experimentally confirmed for hENT1. The best-characterised members of the family, hENT1 and hENT2, possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases. The ENT3 and ENT4 isoforms have more recently also been shown to be genuine nucleoside transporters. All four isoforms are widely distributed in mammalian tissues, although their relative abundance varies: ENT2 is particularly abundant in skeletal muscle. In polarised cells ENT1 and ENT2 are found in the basolateral membrane and, in tandem with concentrative transporters of the SLC28 family, may play a role in transepithelial nucleoside transport. The transporters play key roles in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis, and are also responsible for the cellular uptake of nucleoside analogues used in the treatment of cancers and viral diseases. In addition, by regulating the concentration of adenosine available to cell surface receptors, they influence many physiological processes ranging from cardiovascular activity to neurotransmission.

Keywords

Adenosine Cancer Cardiovascular ENT Equilibrative Nitrobenzylthioinosine Nucleoside Transporter 

Notes

Acknowledgements

This work was supported by the Wellcome Trust, the Medical Research Council of the UK, the Canadian Institutes of Health Research, the National Cancer Institute of Canada, with funds from the Canadian Cancer Society, the Alberta Cancer Board and the Natural Sciences and Engineering Research Council of Canada. J.D.Y. is a Heritage Scientist of the Alberta Heritage Foundation for Medical Research and C.E.C. holds a Canada Research Chair in Oncology.

References

  1. 1.
    Acimovic Y, Coe IR (2002) Molecular evolution of the equilibrative nucleoside transporter family: identification of novel family members in prokaryotes and eukaryotes. Mol Biol Evol 19:2199–2210PubMedGoogle Scholar
  2. 2.
    Ackley MA, Governo RJ, Cass CE, Young JD, Baldwin SA, King A (2003) Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1. J Physiol (Lond) 548:507–517Google Scholar
  3. 3.
    Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402PubMedGoogle Scholar
  4. 4.
    Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216–224PubMedGoogle Scholar
  5. 5.
    Baxter G (2002) Role of adenosine in delayed preconditioning of myocardium. Cardiovasc Res 55:483–494CrossRefPubMedGoogle Scholar
  6. 6.
    Berry ZA (2002) Nucleoside transporters in the heart. PhD Thesis, University of LeedsGoogle Scholar
  7. 7.
    Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE (2002) The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. In: Andersson B, Murray D (eds) Clinically relevant resistance in cancer chemotherapy. Kluwer, Boston, pp 27–47Google Scholar
  8. 8.
    Coe I, Zhang Y, McKenzie T, Naydenova Z (2002) PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett 517:201–205CrossRefPubMedGoogle Scholar
  9. 9.
    Crawford CR, Patel DH, Naeve C, Belt JA (1998) Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 273:5288–5293PubMedGoogle Scholar
  10. 10.
    Dennis DM, Raatikainen P, Martens JR, Belardinelli L (1996) Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea-pig heart. Circulation 94:2551–2559PubMedGoogle Scholar
  11. 11.
    Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415–424CrossRefPubMedGoogle Scholar
  12. 12.
    Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26:621–629CrossRefPubMedGoogle Scholar
  13. 13.
    Griffith DA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153–181PubMedGoogle Scholar
  14. 14.
    Griffiths M, Beaumont N, Yao SYM, Sundaram M, Boumah CE, Davies A, Kwong FYP, Coe I, Cass CE, Young JD, Baldwin SA (1997) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3:89–93PubMedGoogle Scholar
  15. 15.
    Griffiths M, Yao SYM, Abidi F, Phillips SEV, Cass CE, Young JD, Baldwin SA (1997) Molecular Cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 328:739–743PubMedGoogle Scholar
  16. 16.
    Hamilton SR, Yao SYM, Ingram JC, Hadden DA, Ritzel MW, Gallagher MP, Henderson PJF, Cass CE, Young JD, Baldwin SA (2001) Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1. J Biol Chem 276:27981–27988CrossRefPubMedGoogle Scholar
  17. 17.
    Handa M, Choi DS, Caldeiro RM, Messing RO, Gordon AS, Diamond I (2001) Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. Gene 262:301–307CrossRefPubMedGoogle Scholar
  18. 18.
    Huang M, Wang Y, Cogut SB, Mitchell BS, Graves LM (2003) Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther 304:753–760CrossRefPubMedGoogle Scholar
  19. 19.
    Hyde RJ, Cass CE, Young JD, Baldwin SA (2001) The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 18:53–63CrossRefPubMedGoogle Scholar
  20. 20.
    Jennings LL, Hao CH, Cabrita MA, Vickers MF, Baldwin SA, Young JD, Cass CE (2001) Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40:722–731CrossRefPubMedGoogle Scholar
  21. 21.
    Keil GJ, DeLander GE (1995) Time-dependent antinociceptive interactions between opioids and nucleoside transport inhibitors. J Pharmacol Exp Ther 274:1387–1392PubMedGoogle Scholar
  22. 22.
    Kiss A, Farah K, Kim J, Garriock RJ, Drysdale TA, Hammond JR (2000) Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem J 352:363–372CrossRefPubMedGoogle Scholar
  23. 23.
    Lai YR, Bakken AH, Unadkat JD (2002) Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells—localization and vectorial transport studies. J Biol Chem 277:37711–37717CrossRefPubMedGoogle Scholar
  24. 24.
    Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, Koski SL, Coupland RW, Baldwin SA, Young JD, Cass CE (2002) Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8:110–116PubMedGoogle Scholar
  25. 25.
    Mangravite LM, Xiao G, Giacomini KM (2003) Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am J Physiol (in press)Google Scholar
  26. 26.
    Martin BJ, Lasley RD, Mentzer RM (1997) Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. Am J Physiol 41:H1857–H1865Google Scholar
  27. 27.
    Meckling-Gill KA, Guilbert L, Cass CE (1993) CSF-1 stimulates nucleoside transport in S1 macrophages. J Cell Physiol 155:530–538PubMedGoogle Scholar
  28. 28.
    Meester BJ, Shankley NP, Welsh NJ, Meijler FL, Black JW (1998) Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig. Br J Pharmacol 124:729–741PubMedGoogle Scholar
  29. 29.
    Mubagwa K, Flameng W (2001) Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52:25–39CrossRefPubMedGoogle Scholar
  30. 30.
    Musa H, Dobrzynski H, Berry Z, Abidi F, Cass CE, Young JD, Baldwin SA, Boyett, MR (2002) Immunocytochemical demonstration of the equilibrative nucleoside transporter rENT1 in rat sinoatrial node. J Histochem Cytochem 50:305–309PubMedGoogle Scholar
  31. 31.
    Poon A, Sawynok J (1998) Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 74:235–245CrossRefPubMedGoogle Scholar
  32. 32.
    Pressacco J, Wiley JS, Jamieson GP, Erlichman C, Hedley DW (1995) Modulation of the equilibrative nucleoside transporter by inhibitors of DNA-synthesis. Br J Cancer 72:939–942PubMedGoogle Scholar
  33. 33.
    Reiman T, Clarke ML, Dabbagh L, Vsianska M, Coupland RW, Belch AR, Baldwin SA, Young JD, Cass CE, Mackey JR (2002) Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. Leuk Lymph 43:1435–1440CrossRefGoogle Scholar
  34. 34.
    Sandoval IV, Martinez-Arca S, Valdueza J, Palacios S, Holman GD (2000) Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4. J Biol Chem 275:39874–39885CrossRefPubMedGoogle Scholar
  35. 35.
    Sawynok J (1998) Adenosine receptor activation and nociception. Eur J Pharmacol 347:1–11PubMedGoogle Scholar
  36. 36.
    SenGupta DJ, Lum PY, Lai YR, Shubochkina E, Bakken AH, Schneider G, Unadkat JD (2002) A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Biochemistry 41:1512–1519CrossRefPubMedGoogle Scholar
  37. 37.
    Shryock JC, Belardinelli L (1997) Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79(12A):2–10Google Scholar
  38. 38.
    Sundaram M, Yao SYM, Ng AML, Griffiths M, Cass CE, Baldwin SA, Young JD (1998) Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. J Biol Chem 273:21519–21525PubMedGoogle Scholar
  39. 39.
    Sundaram M, Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD (2001) Equilibrative nucleoside transporters: mapping regions of interaction for the substrate analogue nitrobenzylthioinosine (NBMPR) using rat chimeric proteins. Biochemistry 40:8146–8151CrossRefPubMedGoogle Scholar
  40. 40.
    Sundaram M, Yao SYM, Ingram JC, Berry ZA, Abidi F, Cass CE, Baldwin SA, Young JD (2001) Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J Biol Chem 276:45270–45275CrossRefPubMedGoogle Scholar
  41. 41.
    Szkotak AJ, Ng AL, Sawicka J, Baldwin SA, Man SP, Cass CE, Young JD, Duszyk M (2001) Regulation of K+ current in human airway epithelial cells by exogenous and autocrine adenosine. Am J Physiol 281:C1991-C2002Google Scholar
  42. 42.
    Tattersall MHN, Slowiaczek P, De Fazio A (1983) Regional variation in human extracellular purine levels. J Lab Clin Med 102:411–420PubMedGoogle Scholar
  43. 43.
    Vesa J, Peltonen L (2002) Mutated genes in juvenile and variant late infantile neuronal ceroid lipofuscinoses encode lysosomal proteins. Curr Mol Med 2:439–444PubMedGoogle Scholar
  44. 44.
    Vickers MF, Mani RS, Sundaram M, Hogue DL, Young JD, Baldwin SA, Cass CE (1999) Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae - Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochem J 339:21–32CrossRefPubMedGoogle Scholar
  45. 45.
    Visser F, Vickers MF, Ng AL, Baldwin SA, Young JD, Cass CE (2002) Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 277:395–401CrossRefPubMedGoogle Scholar
  46. 46.
    Ward JL, Sherali A, Mo Z-P, Tse C-M (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275:8375–8381CrossRefPubMedGoogle Scholar
  47. 47.
    Ward JL, Leung GP, Toan SV, Tse CM (2003) Functional analysis of site-directed glycosylation mutants of the human equilibrative nucleoside transporter-2. Arch Biochem Biophys 411:19–26CrossRefPubMedGoogle Scholar
  48. 48.
    Wiley JS, Woodruff RK, Jamieson GP, Firkin FC, Sawyer WH (1987) Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia. Aust N Z J Med 17:379–386PubMedGoogle Scholar
  49. 49.
    Williams JB, Lanahan AA (1995) A mammalian delayed-early response gene encodes HNP36, a novel, conserved nucleolar protein. Biochem Biophys Res Commun 213:325–333CrossRefPubMedGoogle Scholar
  50. 50.
    Wright AM, Gati WP, Paterson AR (2000) Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 14:52–60CrossRefPubMedGoogle Scholar
  51. 51.
    Yao SYM, Ng AML, Muzyka WR, Griffiths M, Cass CE, Baldwin SA, Young JD (1997) Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem 272:28423–28430PubMedGoogle Scholar
  52. 52.
    Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD (2001) Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 18:161–167CrossRefPubMedGoogle Scholar
  53. 53.
    Yao SYM, Sundaram M, Chomey EG, Cass CE, Baldwin SA, Young JD (2001) Identification of Cys140 in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2. Biochem J 353:387–393CrossRefPubMedGoogle Scholar
  54. 54.
    Yao SYM, Ng AML, Vickers MF, Sundaram M, Cass EC, Baldwin SA, Young JD (2002) Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2 - Chimeric constructs reveal a role for the ENT2 helix 5–6 region in nucleobase translocation. J Biol Chem 277:24938–24948CrossRefPubMedGoogle Scholar
  55. 55.
    Zhang YW, Shepel PN, Peeling J, Geiger JD, Parkinson FE (2002) Effects of nitrobenzylthioinosine on adenosine levels and neuronal injury in rat forebrain ischemia. Neurosci Res Commun 30:83–89CrossRefGoogle Scholar

Copyright information

© Springer-Verlag  2004

Authors and Affiliations

  • Stephen A. Baldwin
    • 1
  • Paul R. Beal
    • 1
  • Sylvia Y. M. Yao
    • 3
  • Anne E. King
    • 2
  • Carol E. Cass
    • 4
  • James D. Young
    • 3
  1. 1.School of Biochemistry and Molecular BiologyUniversity of LeedsLeedsUK
  2. 2.School of Biomedical SciencesUniversity of LeedsLeedsUK
  3. 3.Membrane Transport Research Group, Department of PhysiologyUniversity of AlbertaEdmontonCanada
  4. 4.Membrane Transport Research Group, Department of Oncology (Cross Cancer Institute)University of AlbertaEdmontonCanada

Personalised recommendations